Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society · 2025
Indocyanine green-enhanced transpupillary thermotherapy in treatment of retinoblastoma: Experience in Indian eyes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Das Abhishek, Subramanian Prema, Maitra Puja, Shah Parag K, Narendran Ventatapathy
Аннотация
PURPOSE: The purpose of the study was to study the outcome of indocyanine green enhanced transpupillary thermotherapy (ICG-E TTT) in the treatment of reactivation of retinoblastoma (RB) showing poor response to standard TTT after 6 cycles of systemic chemotherapy in pigmented Indian eyes.
METHODS: After initial 6 cycles of standard-dose intravenous chemotherapy and focal consolidation with conventional TTT, ICG-E TTT was considered for reactivation of RB postchemotherapy when there was no response to 2 consecutive standard TTT or when there was minimal/inadequate response to 4 or more standard TTT. Examination under general anesthesia was done after 4 weeks, and process was repeated if required. Treatment success was described as achieving a treatment-free follow-up and decreasing the need for further chemotherapy.
RESULTS: Ten eyes of 8 babies (7 with bilateral RB) received ICG enhanced TTT. In 8 out 10 eyes, good regression was noted following ICG E TTT, for a mean of 2 times using a mean power of 350 mW. Seven out of 8 babies did not need re-starting systemic chemotherapy for recurrence. The mean treatment-free follow-up was 6.4 months.
CONCLUSION: Using ICG-enhanced TTT, we achieved longer treatment-free follow-up and a decrease in the need for restarting systemic chemotherapy.
METHODS: After initial 6 cycles of standard-dose intravenous chemotherapy and focal consolidation with conventional TTT, ICG-E TTT was considered for reactivation of RB postchemotherapy when there was no response to 2 consecutive standard TTT or when there was minimal/inadequate response to 4 or more standard TTT. Examination under general anesthesia was done after 4 weeks, and process was repeated if required. Treatment success was described as achieving a treatment-free follow-up and decreasing the need for further chemotherapy.
RESULTS: Ten eyes of 8 babies (7 with bilateral RB) received ICG enhanced TTT. In 8 out 10 eyes, good regression was noted following ICG E TTT, for a mean of 2 times using a mean power of 350 mW. Seven out of 8 babies did not need re-starting systemic chemotherapy for recurrence. The mean treatment-free follow-up was 6.4 months.
CONCLUSION: Using ICG-enhanced TTT, we achieved longer treatment-free follow-up and a decrease in the need for restarting systemic chemotherapy.